生物制剂在银屑病中的应用进展  

Progress of Biologic Agents in the Treatment of Psoriasis

作　　者：盛宇俊[1] 袁涛 黄贺[1] 蔡明龙 张学军[1] SHENG Yujun;YUAN Tao;HUANG He;CAI Minglong;ZHANG Xuejun(Department of Dermatology and Venereology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)

机构地区：[1]安徽医科大学第一附属医院皮肤性病科

出　　处：《皮肤科学通报》2019年第5期528-535,共8页Dermatology Bulletin

摘　　要：银屑病是一种慢性炎症性疾病,甲氨蝶呤、维A酸、环孢素等是系统治疗银屑病的传统药物,但均存在起效慢及不良反应多等缺点。生物制剂尤其是单克隆抗体是FDA批准用于治疗中~重度银屑病的常见药物,本文系统阐述TNF-α拮抗剂、IL-17拮抗剂、IL12/23拮抗剂、IL-23拮抗剂治疗银屑病的临床疗效和安全性。Psoriasis is a chronic inflammatory disease and methotrexate,retinoic acid and cyclosporine are traditional drugs for its systematic treatment. However,the clinical effect is slow and adverse reactions are not a few. Biological agents,especially monoclonal antibodies are commonly used in the treatment of moderate to severe psoriasis that approved by FDA. This review systematically describes the clinical efficacy and safety of TNF-αntagonists,IL-17 antagonists,IL-12/23 antagonists and IL-23 antagonists in the treatment of psoriasis.

关 键 词：银屑病 生物制剂 临床疗效 安全性 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]